This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Aim: 1. To develop a rat model to study vincristine-induced SAIDH 2. To determine the possible role of erythropoietin in reducing
the hyponatremia and survival rate associated with vincristine-induced SAIDH.
Methods: Rats were allocated into five groups (n=4-8 each). All groups were i.p. dosed 0.15 ug/Kg vincristine sulphate (VCR) for 15
days 6 days per week. Groups 2, 3 and 5 were administered either 40 U/Kg or 80 U/Kg erythropoietin i.p. along with the VCR. Groups
4 and 5 were administered 40 mg/Kg posaconazole (PSZ) orally starting the day of VCR administration. Rats’ weights and survival
rates were measured daily and their serum sodium and potassium levels were measured at days 0, 5, 9 and 15.
Results: No rats survived after day 12 of dosing. The VCR-induced SAIDH rat model showed 3.4% and 4.1% reduced sodium levels
on days 5 & 9, respectively. Their serum potassium level showed no significant change on day 5 and 8% decrease on day 9. The rats
exhibited weight reduction of 10% and 18% on days 5 and 9, respectively. Erythropoietin 40 U/Kg treated rats showed significantly
less hyponatremia (0.6% decrease) and 24% increase in potassium levels on day 5. However, increasing the erythropoietin therapy
duration beyond 5 days and/or dose (80 U/Kg treated groups) resulted in increased hyponatremia and demolished rats’ survival.
PSZ-VCR dosed rats and PSZ-VCR-erythropoietin dosed rats survived only for 4 days. Posaconazole-VCR treated groups showed
increased VCR toxicity with ~12% increase in serum potassium levels, however, serum sodium levels showed no significant difference
during the 4 days.
Conclusion: Initial rat model to study vincristine-induced SAIDH was developed. Co-administration of low dose erythropoietin
(40 U/Kg) for short duration, ≤5 days, showed a potential benefit in reversing the VCR-induced hyponatremia however, we need to
consider controlling the induced hyperkalemia. Human serum sodium, potassium and BUN levels for patients administered VCR
alone or VCR along with erythropoietin in ALL treatment protocols needs to be studied to confirm such trends.
Malak Abouayana is a third-year undergraduate pharmacy student, Faculty of Pharmacy, Alexandria University.